Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy
Clinical trial NCT07177196 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07177196
- Sponsor
- n-Lorem Foundation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-28
- Primary completion
- 2027-08-01
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.